These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

418 related articles for article (PubMed ID: 19450663)

  • 1. Bifeprunox and aripiprazole suppress in vivo VTA dopaminergic neuronal activity via D2 and not D3 dopamine autoreceptor activation.
    Etievant A; Bétry C; Arnt J; Haddjeri N
    Neurosci Lett; 2009 Aug; 460(1):82-6. PubMed ID: 19450663
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of bifeprunox and aripiprazole on rat serotonin and dopamine neuronal activity and anxiolytic behaviour.
    Dahan L; Husum H; Mnie-Filali O; Arnt J; Hertel P; Haddjeri N
    J Psychopharmacol; 2009 Mar; 23(2):177-89. PubMed ID: 18515444
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Partial agonist properties of the antipsychotics SSR181507, aripiprazole and bifeprunox at dopamine D2 receptors: G protein activation and prolactin release.
    Cosi C; Carilla-Durand E; Assié MB; Ormiere AM; Maraval M; Leduc N; Newman-Tancredi A
    Eur J Pharmacol; 2006 Mar; 535(1-3):135-44. PubMed ID: 16554049
    [TBL] [Abstract][Full Text] [Related]  

  • 4. S33084, a novel, potent, selective, and competitive antagonist at dopamine D(3)-receptors: I. Receptorial, electrophysiological and neurochemical profile compared with GR218,231 and L741,626.
    Millan MJ; Gobert A; Newman-Tancredi A; Lejeune F; Cussac D; Rivet JM; Audinot V; Dubuffet T; Lavielle G
    J Pharmacol Exp Ther; 2000 Jun; 293(3):1048-62. PubMed ID: 10869410
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Partial agonist actions of aripiprazole and the candidate antipsychotics S33592, bifeprunox, N-desmethylclozapine and preclamol at dopamine D(2L) receptors are modified by co-transfection of D(3) receptors: potential role of heterodimer formation.
    Novi F; Millan MJ; Corsini GU; Maggio R
    J Neurochem; 2007 Aug; 102(4):1410-24. PubMed ID: 17532788
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vivo effects of pardoprunox (SLV308), a partial D₂/D₃ receptor and 5-HT1A receptor agonist, on rat dopamine and serotonin neuronal activity.
    Bétry C; Etiévant A; Lambás-Señas L; McCreary AC; Haddjeri N
    Synapse; 2011 Oct; 65(10):1042-51. PubMed ID: 21446003
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discriminative stimulus properties of S32504, a novel D3/D2 receptor agonist and antiparkinson agent, in rats: attenuation by the antipsychotics, aripiprazole, bifeprunox, N-desmethylclozapine, and by selective antagonists at dopamine D2 but not D3 receptors.
    Millan MJ; Iob L; Péglion JL; Dekeyne A
    Psychopharmacology (Berl); 2007 Apr; 191(3):767-82. PubMed ID: 17047933
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dopamine D2(High) receptors moderately elevated by bifeprunox and aripiprazole.
    Seeman P
    Synapse; 2008 Dec; 62(12):902-8. PubMed ID: 18792990
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vivo actions of aripiprazole on serotonergic and dopaminergic systems in rodent brain.
    Bortolozzi A; Díaz-Mataix L; Toth M; Celada P; Artigas F
    Psychopharmacology (Berl); 2007 Apr; 191(3):745-58. PubMed ID: 17265076
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preferential modulation of mesolimbic vs. nigrostriatal dopaminergic function by serotonin(2C/2B) receptor agonists: a combined in vivo electrophysiological and microdialysis study.
    Di Giovanni G; Di Matteo V; Di Mascio M; Esposito E
    Synapse; 2000 Jan; 35(1):53-61. PubMed ID: 10579808
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stimulation of serotonin2C receptors blocks the hyperactivation of midbrain dopamine neurons induced by nicotine administration.
    Pierucci M; Di Matteo V; Esposito E
    J Pharmacol Exp Ther; 2004 Apr; 309(1):109-18. PubMed ID: 14722316
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differences in agonist/antagonist properties at human dopamine D(2) receptors between aripiprazole, bifeprunox and SDZ 208-912.
    Tadori Y; Kitagawa H; Forbes RA; McQuade RD; Stark A; Kikuchi T
    Eur J Pharmacol; 2007 Nov; 574(2-3):103-11. PubMed ID: 17692841
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of acute and repeated administration of amisulpride, a dopamine D2/D3 receptor antagonist, on the electrical activity of midbrain dopaminergic neurons.
    Di Giovanni G; Di Mascio M; Di Matteo V; Esposito E
    J Pharmacol Exp Ther; 1998 Oct; 287(1):51-7. PubMed ID: 9765321
    [TBL] [Abstract][Full Text] [Related]  

  • 14. S33138 [N-[4-[2-[(3aS,9bR)-8-cyano-1,3a,4,9b-tetrahydro[1]-benzopyrano[3,4-c]pyrrol-2(3H)-yl)-ethyl]phenylacetamide], a preferential dopamine D3 versus D2 receptor antagonist and potential antipsychotic agent. II. A neurochemical, electrophysiological and behavioral characterization in vivo.
    Millan MJ; Svenningsson P; Ashby CR; Hill M; Egeland M; Dekeyne A; Brocco M; Di Cara B; Lejeune F; Thomasson N; Munoz C; Mocaër E; Crossman A; Cistarelli L; Girardon S; Iob L; Veiga S; Gobert A
    J Pharmacol Exp Ther; 2008 Feb; 324(2):600-11. PubMed ID: 18024787
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bifeprunox: a partial agonist at dopamine D2 and serotonin 1A receptors, influences nicotine-seeking behaviour in response to drug-associated stimuli in rats.
    Di Clemente A; Franchi C; Orrù A; Arnt J; Cervo L
    Addict Biol; 2012 Mar; 17(2):274-86. PubMed ID: 21521422
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Receptor reserve-dependent properties of antipsychotics at human dopamine D2 receptors.
    Tadori Y; Forbes RA; McQuade RD; Kikuchi T
    Eur J Pharmacol; 2009 Apr; 607(1-3):35-40. PubMed ID: 19217900
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cariprazine (RGH-188), a dopamine D(3) receptor-preferring, D(3)/D(2) dopamine receptor antagonist-partial agonist antipsychotic candidate: in vitro and neurochemical profile.
    Kiss B; Horváth A; Némethy Z; Schmidt E; Laszlovszky I; Bugovics G; Fazekas K; Hornok K; Orosz S; Gyertyán I; Agai-Csongor E; Domány G; Tihanyi K; Adham N; Szombathelyi Z
    J Pharmacol Exp Ther; 2010 Apr; 333(1):328-40. PubMed ID: 20093397
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Pharmacology of antipsychotics at human dopamine D2 and D3 receptors].
    Tadori Y; Kikuchi T
    Nihon Shinkei Seishin Yakurigaku Zasshi; 2012 Feb; 32(1):9-18. PubMed ID: 22568121
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Induction of burst firing in ventral tegmental area dopaminergic neurons by activation of serotonin (5-HT)1A receptors: WAY 100,635-reversible actions of the highly selective ligands, flesinoxan and S 15535.
    Lejeune F; Millan MJ
    Synapse; 1998 Oct; 30(2):172-80. PubMed ID: 9723787
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of acute and chronic administration of the selective 5-HT2C receptor antagonist SB-243213 on midbrain dopamine neurons in the rat: an in vivo extracellular single cell study.
    Blackburn TP; Minabe Y; Middlemiss DN; Shirayama Y; Hashimoto K; Ashby CR
    Synapse; 2002 Dec; 46(3):129-39. PubMed ID: 12325040
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.